1. Home
  2. DOGZ vs SGMT Comparison

DOGZ vs SGMT Comparison

Compare DOGZ & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

DOGZ

Dogness (International) Corporation

N/A

Current Price

$1.01

Market Cap

153.5M

ML Signal

N/A

Logo Sagimet Biosciences Inc. Series A

SGMT

Sagimet Biosciences Inc. Series A

HOLD

Current Price

$7.79

Market Cap

169.4M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
DOGZ
SGMT
Founded
2003
2006
Country
China
United States
Employees
N/A
N/A
Industry
Miscellaneous manufacturing industries
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
153.5M
169.4M
IPO Year
2017
2021

Fundamental Metrics

Financial Performance
Metric
DOGZ
SGMT
Price
$1.01
$7.79
Analyst Decision
Strong Buy
Analyst Count
0
8
Target Price
N/A
$26.13
AVG Volume (30 Days)
31.3K
1.4M
Earning Date
04-01-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$2,000,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.81
$4.50
52 Week High
$16.59
$11.41

Technical Indicators

Market Signals
Indicator
DOGZ
SGMT
Relative Strength Index (RSI) 42.29 58.62
Support Level $0.99 $7.04
Resistance Level $1.47 $8.80
Average True Range (ATR) 0.06 0.50
MACD -0.01 0.03
Stochastic Oscillator 44.64 74.60

Price Performance

Historical Comparison
DOGZ
SGMT

About DOGZ Dogness (International) Corporation

Dogness (International) Corp designs, manufactures pet products, including leashes and smart products, and lanyards. The company designs, processes, and manufactures fashionable and high-quality leashes, collars, and harnesses to complement cats' and dogs' appearances, as well as intelligent pet products. The company also provides dyeing services to external customers, as well as pet grooming services. The dyeing service is to utilize the existing production capacity and the pet grooming service is immaterial. Geographically, it generates maximum revenue from Mainland China and also has a presence in the United States, Europe, Australia, Canada, Central, and South America, Japan, and other Asian countries and regions.

About SGMT Sagimet Biosciences Inc. Series A

Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.

Share on Social Networks: